Reply letter regarding seroconversion of hepatitis B surface antigen in a successful long-term immune cohort

Reply letter regarding seroconversion of hepatitis B surface antigen in a successful long-term immune cohort

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Human vaccines & immunotherapeutics 2021-08, Vol.17 (8), p.2775-2776
Hauptverfasser: Zheng, Zhigang, Zeng, Qing-Lei, Zhou, Yi-Hua
Format: Artikel
Sprache:eng
Schlagworte:
Biotechnology & Applied Microbiology
Cohort Studies
Hepatitis B e Antigens
Hepatitis B Surface Antigens
Hepatitis B, Chronic - therapy
Humans
Immunology
Letter
Letter To The Editor
Life Sciences & Biomedicine
Science & Technology
Seroconversion
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
container_end_page 2776
container_issue 8
container_start_page 2775
container_title Human vaccines & immunotherapeutics
container_volume 17
creator Zheng, Zhigang
Zeng, Qing-Lei
Zhou, Yi-Hua
description
doi_str_mv 10.1080/21645515.2021.1897488
format Article
fullrecord <record><control><sourceid>proquest_pubme</sourceid><recordid>TN_cdi_pubmed_primary_33849386</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><doaj_id>oai_doaj_org_article_19e1509fe70f47faaad5ce4eef45b774</doaj_id><sourcerecordid>2512742410</sourcerecordid><originalsourceid>FETCH-LOGICAL-c482t-49ec506b4c8c979ca7eafc5a0da717b59bc0f0489ad20a403c677d9d0c00d7653</originalsourceid><addsrcrecordid>eNqNkl9rHCEUxYfS0oQ0H6HFx0LZrc7oOPNS2iz9EwgUSgt9kzvOddfg6FadhP32dbubpXkpvT4o13N-KseqesnoktGOvq1Zy4VgYlnTmi1Z10vedU-q831_IQT_-fS0ZuKsukzplpaStOZt-7w6a5qO903XnlfuG27djjjMGSOJuIY4Wr8mCWPQwd9hTDZ4EgzZ4BayzTaRK5LmaEAjAZ_tGj2xnkBpao0pmdkRF_x6UYATsdM0eyQ6bELML6pnBlzCy-N8Uf349PH76svi5uvn69WHm4XmXZ0XvEctaDtw3ele9hokgtEC6AiSyUH0g6aG8q6HsabAaaNbKcd-pJrSUbaiuaiuD9wxwK3aRjtB3KkAVv1phLhWELPVDhXrkQnaG5TUcGkAYBQaOaLhYpCSF9a7A2s7DxOOGn2O4B5BH-94u1HrcKc6LoXouwJ4fQTE8GvGlNVkk0bnwGOYk6oFqyWvOaNFKg5SHUNKEc3pGEbVPnj1ELzaB6-OwRffq7_veHI9xFwE3UFwj0MwSVv0Gk-y8jNaTlkZ-2Irm0vQwa_C7HOxvvl_a1G_P6itNyFOcB-iG1WGnQvRRPDaJtX8-zG_Aevd4Lk</addsrcrecordid><sourcetype>Open Website</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2512742410</pqid></control><display><type>article</type><title>Reply letter regarding seroconversion of hepatitis B surface antigen in a successful long-term immune cohort</title><source>MEDLINE</source><source>Web of Science - Science Citation Index Expanded - 2021&lt;img src="https://exlibris-pub.s3.amazonaws.com/fromwos-v2.jpg" /&gt;</source><source>PubMed Central</source><source>Alma/SFX Local Collection</source><creator>Zheng, Zhigang ; Zeng, Qing-Lei ; Zhou, Yi-Hua</creator><creatorcontrib>Zheng, Zhigang ; Zeng, Qing-Lei ; Zhou, Yi-Hua</creatorcontrib><identifier>ISSN: 2164-5515</identifier><identifier>EISSN: 2164-554X</identifier><identifier>DOI: 10.1080/21645515.2021.1897488</identifier><identifier>PMID: 33849386</identifier><language>eng</language><publisher>PHILADELPHIA: Taylor &amp; Francis</publisher><subject>Biotechnology &amp; Applied Microbiology ; Cohort Studies ; Hepatitis B e Antigens ; Hepatitis B Surface Antigens ; Hepatitis B, Chronic - therapy ; Humans ; Immunology ; Letter ; Letter To The Editor ; Life Sciences &amp; Biomedicine ; Science &amp; Technology ; Seroconversion</subject><ispartof>Human vaccines &amp; immunotherapeutics, 2021-08, Vol.17 (8), p.2775-2776</ispartof><rights>2021 Taylor &amp; Francis Group, LLC 2021</rights><rights>2021 Taylor &amp; Francis Group, LLC 2021 Taylor &amp; Francis</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>true</woscitedreferencessubscribed><woscitedreferencescount>0</woscitedreferencescount><woscitedreferencesoriginalsourcerecordid>wos000640101000001</woscitedreferencesoriginalsourcerecordid><cites>FETCH-LOGICAL-c482t-49ec506b4c8c979ca7eafc5a0da717b59bc0f0489ad20a403c677d9d0c00d7653</cites><orcidid>0000-0001-8880-0392 ; 0000-0001-8627-1263</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC8475598/pdf/$$EPDF$$P50$$Gpubmedcentral$$H</linktopdf><linktohtml>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC8475598/$$EHTML$$P50$$Gpubmedcentral$$H</linktohtml><link.rule.ids>230,315,728,781,785,886,27929,27930,39263,53796,53798</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/33849386$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Zheng, Zhigang</creatorcontrib><creatorcontrib>Zeng, Qing-Lei</creatorcontrib><creatorcontrib>Zhou, Yi-Hua</creatorcontrib><title>Reply letter regarding seroconversion of hepatitis B surface antigen in a successful long-term immune cohort</title><title>Human vaccines &amp; immunotherapeutics</title><addtitle>HUM VACC IMMUNOTHER</addtitle><addtitle>Hum Vaccin Immunother</addtitle><subject>Biotechnology &amp; Applied Microbiology</subject><subject>Cohort Studies</subject><subject>Hepatitis B e Antigens</subject><subject>Hepatitis B Surface Antigens</subject><subject>Hepatitis B, Chronic - therapy</subject><subject>Humans</subject><subject>Immunology</subject><subject>Letter</subject><subject>Letter To The Editor</subject><subject>Life Sciences &amp; Biomedicine</subject><subject>Science &amp; Technology</subject><subject>Seroconversion</subject><issn>2164-5515</issn><issn>2164-554X</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2021</creationdate><recordtype>article</recordtype><sourceid>HGBXW</sourceid><sourceid>EIF</sourceid><sourceid>DOA</sourceid><recordid>eNqNkl9rHCEUxYfS0oQ0H6HFx0LZrc7oOPNS2iz9EwgUSgt9kzvOddfg6FadhP32dbubpXkpvT4o13N-KseqesnoktGOvq1Zy4VgYlnTmi1Z10vedU-q831_IQT_-fS0ZuKsukzplpaStOZt-7w6a5qO903XnlfuG27djjjMGSOJuIY4Wr8mCWPQwd9hTDZ4EgzZ4BayzTaRK5LmaEAjAZ_tGj2xnkBpao0pmdkRF_x6UYATsdM0eyQ6bELML6pnBlzCy-N8Uf349PH76svi5uvn69WHm4XmXZ0XvEctaDtw3ele9hokgtEC6AiSyUH0g6aG8q6HsabAaaNbKcd-pJrSUbaiuaiuD9wxwK3aRjtB3KkAVv1phLhWELPVDhXrkQnaG5TUcGkAYBQaOaLhYpCSF9a7A2s7DxOOGn2O4B5BH-94u1HrcKc6LoXouwJ4fQTE8GvGlNVkk0bnwGOYk6oFqyWvOaNFKg5SHUNKEc3pGEbVPnj1ELzaB6-OwRffq7_veHI9xFwE3UFwj0MwSVv0Gk-y8jNaTlkZ-2Irm0vQwa_C7HOxvvl_a1G_P6itNyFOcB-iG1WGnQvRRPDaJtX8-zG_Aevd4Lk</recordid><startdate>20210803</startdate><enddate>20210803</enddate><creator>Zheng, Zhigang</creator><creator>Zeng, Qing-Lei</creator><creator>Zhou, Yi-Hua</creator><general>Taylor &amp; Francis</general><general>Taylor &amp; Francis Group</general><scope>BLEPL</scope><scope>DTL</scope><scope>HGBXW</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope><scope>5PM</scope><scope>DOA</scope><orcidid>https://orcid.org/0000-0001-8880-0392</orcidid><orcidid>https://orcid.org/0000-0001-8627-1263</orcidid></search><sort><creationdate>20210803</creationdate><title>Reply letter regarding seroconversion of hepatitis B surface antigen in a successful long-term immune cohort</title><author>Zheng, Zhigang ; Zeng, Qing-Lei ; Zhou, Yi-Hua</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c482t-49ec506b4c8c979ca7eafc5a0da717b59bc0f0489ad20a403c677d9d0c00d7653</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2021</creationdate><topic>Biotechnology &amp; Applied Microbiology</topic><topic>Cohort Studies</topic><topic>Hepatitis B e Antigens</topic><topic>Hepatitis B Surface Antigens</topic><topic>Hepatitis B, Chronic - therapy</topic><topic>Humans</topic><topic>Immunology</topic><topic>Letter</topic><topic>Letter To The Editor</topic><topic>Life Sciences &amp; Biomedicine</topic><topic>Science &amp; Technology</topic><topic>Seroconversion</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Zheng, Zhigang</creatorcontrib><creatorcontrib>Zeng, Qing-Lei</creatorcontrib><creatorcontrib>Zhou, Yi-Hua</creatorcontrib><collection>Web of Science Core Collection</collection><collection>Science Citation Index Expanded</collection><collection>Web of Science - Science Citation Index Expanded - 2021</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><collection>PubMed Central (Full Participant titles)</collection><collection>DOAJ Directory of Open Access Journals</collection><jtitle>Human vaccines &amp; immunotherapeutics</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Zheng, Zhigang</au><au>Zeng, Qing-Lei</au><au>Zhou, Yi-Hua</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Reply letter regarding seroconversion of hepatitis B surface antigen in a successful long-term immune cohort</atitle><jtitle>Human vaccines &amp; immunotherapeutics</jtitle><stitle>HUM VACC IMMUNOTHER</stitle><addtitle>Hum Vaccin Immunother</addtitle><date>2021-08-03</date><risdate>2021</risdate><volume>17</volume><issue>8</issue><spage>2775</spage><epage>2776</epage><pages>2775-2776</pages><issn>2164-5515</issn><eissn>2164-554X</eissn><cop>PHILADELPHIA</cop><pub>Taylor &amp; Francis</pub><pmid>33849386</pmid><doi>10.1080/21645515.2021.1897488</doi><tpages>2</tpages><orcidid>https://orcid.org/0000-0001-8880-0392</orcidid><orcidid>https://orcid.org/0000-0001-8627-1263</orcidid><oa>free_for_read</oa></addata></record>
fulltext fulltext
identifier ISSN: 2164-5515
ispartof Human vaccines & immunotherapeutics, 2021-08, Vol.17 (8), p.2775-2776
issn 2164-5515
2164-554X
language eng
recordid cdi_pubmed_primary_33849386
source MEDLINE; Web of Science - Science Citation Index Expanded - 2021<img src="https://exlibris-pub.s3.amazonaws.com/fromwos-v2.jpg" />; PubMed Central; Alma/SFX Local Collection
subjects Biotechnology & Applied Microbiology
Cohort Studies
Hepatitis B e Antigens
Hepatitis B Surface Antigens
Hepatitis B, Chronic - therapy
Humans
Immunology
Letter
Letter To The Editor
Life Sciences & Biomedicine
Science & Technology
Seroconversion
title Reply letter regarding seroconversion of hepatitis B surface antigen in a successful long-term immune cohort
url https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-13T01%3A52%3A17IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_pubme&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Reply%20letter%20regarding%20seroconversion%20of%20hepatitis%20B%20surface%20antigen%20in%20a%20successful%20long-term%20immune%20cohort&rft.jtitle=Human%20vaccines%20&%20immunotherapeutics&rft.au=Zheng,%20Zhigang&rft.date=2021-08-03&rft.volume=17&rft.issue=8&rft.spage=2775&rft.epage=2776&rft.pages=2775-2776&rft.issn=2164-5515&rft.eissn=2164-554X&rft_id=info:doi/10.1080/21645515.2021.1897488&rft_dat=%3Cproquest_pubme%3E2512742410%3C/proquest_pubme%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=2512742410&rft_id=info:pmid/33849386&rft_doaj_id=oai_doaj_org_article_19e1509fe70f47faaad5ce4eef45b774&rfr_iscdi=true